BCTX
BriaCell TherapeuticsFNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-06-11
Current thesis
Composite grade F from latest DB weights. Momentum 1.5 / Value 41.0
Posture
Defensive
Lead driver
Value
What changed
Value remains the lead driver in the composite, 7D delta -0.1.
What can break
Mixed signals. Wait for cleaner trend confirmation.
Momentum
2
Value
41
Sentiment
N/A
Setup hits (3d)
0 · Net Neutral
AI TargetsBase - · Bull - · Bear -
Data freshness
Prices
As of 2026-06-11
Fundamentals
As of 2026-06-08 • Vendor: Data Vendor v1
Scores
As of 2026-06-11 • Model: HYBRID_IC_RP
AI Memo
Unavailable: No memo yet
Investment thesisAs of 2026-06-11
Investment thesis
As of 2026-06-11
Supporting evidence
What
Grade F · Defensive
Confidence Medium · Net Neutral
Why
Momentum2 · Δ7d -
Value41 · Δ7d -0.1
SentimentN/A · Δ7d -
So what
Weak posture (Net Neutral). Prioritize risk control and patience.
Lead driver: Value · See fundamentals
Momentum
2
52% active weight
Current posture
7d trendTrend unavailable
Trend unavailable
Δ7d
-
Δ21d
-
Value
41
48% active weight
Current posture
7d trendFlat
Δ7d
-0.1
Δ21d
-0.1
Sentiment
N/A
Coverage pending
No current score
7d trendTrend unavailable
Trend unavailable
Δ7d
-
Δ21d
-
Why this grade
Composite grade F. Momentum 1.5 / Value 41.0
Fundamentals (TTM)As of 2026-06-08
Fundamentals (TTM)
As of 2026-06-08
Market Cap
$26.69M
Beta
1.88
Shares Out
1.88M
P/E (TTM) · Derived
-0.2
P/S (TTM)
-
P/FCF (TTM) · Derived
-0.42
Rev YoY
-
EPS YoY
+86.7%
Gross Margin
-
Op Margin
-
Net Debt
-$17.87M
Current Ratio
3.42
As of 2026-06-11 • Updated nightlySource: Internal modelMethodology